CO2022018547A2 - Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413 - Google Patents

Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413

Info

Publication number
CO2022018547A2
CO2022018547A2 CONC2022/0018547A CO2022018547A CO2022018547A2 CO 2022018547 A2 CO2022018547 A2 CO 2022018547A2 CO 2022018547 A CO2022018547 A CO 2022018547A CO 2022018547 A2 CO2022018547 A2 CO 2022018547A2
Authority
CO
Colombia
Prior art keywords
high affinity
serine
affinity antibodies
antibodies directed
tau phosphorylated
Prior art date
Application number
CONC2022/0018547A
Other languages
English (en)
Inventor
Jeanne E Baker
Batteur Sophie Parmentier
Ming-Tang Chen
Alan C Cheng
Chung-Ming Hsieh
Carl Mieczkowski
Sokreine Suon
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of CO2022018547A2 publication Critical patent/CO2022018547A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se proporcionan anticuerpos de alta afinidad o fragmentos de unión a antígeno de los mismos que se unen específicamente a tau-pS413 humana. También se proporcionan composiciones, kits, métodos y usos en los que están implicados tales anticuerpos o fragmentos de unión a antígeno de los mismos
CONC2022/0018547A 2020-06-25 2022-12-21 Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413 CO2022018547A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063044291P 2020-06-25 2020-06-25
PCT/US2021/038591 WO2021262791A1 (en) 2020-06-25 2021-06-23 High affinity antibodies targeting tau phosphorylated at serine 413

Publications (1)

Publication Number Publication Date
CO2022018547A2 true CO2022018547A2 (es) 2022-12-30

Family

ID=76959092

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0018547A CO2022018547A2 (es) 2020-06-25 2022-12-21 Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413

Country Status (18)

Country Link
US (2) US20230265175A1 (es)
EP (1) EP4171633A1 (es)
JP (1) JP2023528535A (es)
KR (1) KR20230023802A (es)
CN (1) CN116723856A (es)
AR (1) AR122721A1 (es)
AU (1) AU2021297873A1 (es)
BR (1) BR112022026575A2 (es)
CA (1) CA3183835A1 (es)
CL (1) CL2022003723A1 (es)
CO (1) CO2022018547A2 (es)
DO (1) DOP2022000295A (es)
EC (1) ECSP23003930A (es)
IL (1) IL299292A (es)
MX (1) MX2022016322A (es)
PE (1) PE20230840A1 (es)
TW (1) TW202216759A (es)
WO (1) WO2021262791A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
MXPA01005515A (es) 1998-12-01 2003-07-14 Protein Design Labs Inc Anticuerpos humanizados para gamma-interferon.
IL143641A0 (en) 1998-12-09 2002-04-21 A method for manufacturing glycoproteins having human-type glycosylation
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
PT1522590E (pt) 2000-06-28 2009-10-26 Glycofi Inc Métodos para a produção de glicoproteínas modificadas
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US7632983B2 (en) 2000-07-31 2009-12-15 Biolex Therapeutics, Inc. Expression of monoclonal antibodies in duckweed
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
WO2003086310A2 (en) 2002-04-12 2003-10-23 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
WO2005120571A2 (en) 2004-06-07 2005-12-22 Ramot At Tel Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
JP5249587B2 (ja) 2005-02-18 2013-07-31 メダレックス， インク． フコシル残基を欠く前立腺特異的膜抗原（ｐｓｍａ）に対するモノクローナル抗体
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
EP1876185A1 (en) 2006-07-04 2008-01-09 F. Hoffmann-La Roche Ag An antibody which recognizes phosphorylated polypeptides
WO2011133919A1 (en) 2010-04-22 2011-10-27 Janssen Alzheimer Immunotherapy Use of tau to monitor immunotherapy
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2440234A4 (en) 2009-06-10 2013-11-06 Univ New York IMMUNOLOGICAL TARGETING OF PATHOLOGICAL TAU PROTEINS
CN102574915B (zh) 2009-08-06 2014-10-22 伊缪纳斯制药株式会社 特异性结合Aβ寡聚体的抗体及其用途
ES2548686T3 (es) 2010-10-07 2015-10-20 Ac Immune S.A. Anticuerpos que reconocen fosfo-Tau
US8940272B2 (en) 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
EP3578567A1 (en) 2011-12-20 2019-12-11 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
NZ630536A (en) 2012-05-31 2017-03-31 Teijin Pharma Ltd Therapeutic agent or prophylactic agent for dementia
PT2885010T (pt) 2012-08-16 2020-03-11 Ipierian Inc Métodos de tratamento de uma tauopatia
KR102234324B1 (ko) 2012-12-21 2021-03-31 바이오젠 엠에이 인코포레이티드 인간 항-타우 항체
KR102153649B1 (ko) 2013-04-25 2020-09-09 루미리즈 홀딩 비.브이. 발광 다이오드 부품
TWI664190B (zh) 2014-06-27 2019-07-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗－ｔａｕ抗體
WO2016112078A2 (en) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
WO2017005734A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
CA2991264C (en) 2015-07-06 2023-10-10 Ucb Biopharma Sprl Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
JOP20180014A1 (ar) 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه

Also Published As

Publication number Publication date
TW202216759A (zh) 2022-05-01
CL2022003723A1 (es) 2023-05-19
JP2023528535A (ja) 2023-07-04
ECSP23003930A (es) 2023-07-31
KR20230023802A (ko) 2023-02-17
US20230167168A9 (en) 2023-06-01
CA3183835A1 (en) 2021-12-30
US20230265175A1 (en) 2023-08-24
WO2021262791A1 (en) 2021-12-30
MX2022016322A (es) 2023-01-24
US11702467B2 (en) 2023-07-18
EP4171633A1 (en) 2023-05-03
CN116723856A (zh) 2023-09-08
BR112022026575A2 (pt) 2023-01-17
IL299292A (en) 2023-02-01
AU2021297873A1 (en) 2023-02-09
PE20230840A1 (es) 2023-05-19
AR122721A1 (es) 2022-09-28
DOP2022000295A (es) 2023-02-15
US20210403541A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
DOP2022000295A (es) Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413
CL2021001686A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378)
CO2018005932A2 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
CL2021000517A1 (es) Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
CL2019002310A1 (es) Receptores quiméricos y métodos de uso de los mismos (divisional solicitud 201802797)
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
PE20201341A1 (es) Anticuerpos de union a gprc5d
CL2021002696A1 (es) Anticuerpos anti-ige (divisional de solicitud 201803556)
BR112018001638A8 (pt) construtos de anticorpo biespecífico que se ligam à mesotelina e cd3
BR112022001368A2 (pt) Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos
CO2020012360A2 (es) Anticuerpos multiespecíficos y utilización de los mismos
ECSP17080733A (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
CL2021002039A1 (es) Agentes de unión a c3 y métodos para su uso (divisional de la solicitud n° 202002522)
CL2022001622A1 (es) Agentes de unión a ilt3 y métodos de uso de los mismos
BR112021026089A2 (pt) Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
CO2022018537A2 (es) Agentes de unión a lair-1 y métodos para su uso
CO2021015254A2 (es) Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y métodos de uso de estos
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
CL2021001607A1 (es) Anticuerpos anti-pmel17 y conjugados de los mismos
CO2023015915A2 (es) Anticuerpos anti-ccr8
DOP2023000005A (es) Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas
CO2021017414A2 (es) Anticuerpos anti-angpt2
CL2021002501A1 (es) Compuestos novedosos y métodos de uso de los mismos.
BR112023021256A2 (pt) Anticorpos humanos para artemina e métodos de uso dos mesmos